Safer use of clozapine
- PMID: 35411581
- DOI: 10.1111/acps.13427
Safer use of clozapine
Comment on
-
Risk factors for clozapine-induced myocarditis and cardiomyopathy: A systematic review and meta-analysis.Acta Psychiatr Scand. 2022 May;145(5):442-455. doi: 10.1111/acps.13398. Epub 2022 Feb 4. Acta Psychiatr Scand. 2022. PMID: 35067911
References
REFERENCES
-
- Bachmann CJ, Aagaard L, Bernardo M, et al. International trends in clozapine use: a study in 17 countries. Acta Psychiatr Scand. 2017;136(1):37-51.
-
- Samara MT, Dold M, Gianatsi M, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry. 2016;73(3):199-210.
-
- Taylor D, Vallianatou K, Whiskey E, Dzahini O, MacCabe J. Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis. NPJ Schizophr. 2022;8(1):21. 10.1038/s41537-022-00232-0
-
- Handley SA, Every-Palmer S, Ismail A, Flanagan RJ. Clozapine-induced gastrointestinal hypomotility: presenting features and outcomes, UK pharmacovigilance reports, 1992-2017. Br J Psychiatry. 2022;1-9. 10.1192/bjp.2022.24
-
- Vickers M, Ramineni V, Malacova E, et al. Risk factors for clozapine-induced myocarditis and cardiomyopathy: A systematic review and meta-analysis. Acta Psychiatr Scand. 2022;145(4):442-455.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources